Cargando…

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern

Severe acute respiratory syndrome coronavirus-2 (SAR-CoV-2) causes coronavirus disease 2019 (COVID19) that is responsible for short and long-term disease, as well as death, in susceptible hosts. The receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) protein binds to cell surface angiotensin c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deshpande, Ashlesha, Harris, Bethany D., Martinez-Sobrido, Luis, Kobie, James J., Walter, Mark R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212047/ https://www.ncbi.nlm.nih.gov/pubmed/34149735 http://dx.doi.org/10.3389/fimmu.2021.691715

Ejemplares similares

Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency
por: Mariotti, Sabrina, et al.
Publicado: (2021)

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants
por: Lin, Wei-Shuo, et al.
Publicado: (2021)

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
por: Fan, Chengcheng, et al.
Publicado: (2022)

The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
por: Tolbert, William D., et al.
Publicado: (2023)

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants
por: Carnell, George W., et al.
Publicado: (2023)

Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
por: Hernández-Luis, Pablo, et al.
Publicado: (2022)

Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents
por: Wang, Zheng, et al.
Publicado: (2023)

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
por: Favorskaya, Irina A., et al.
Publicado: (2022)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies
por: Ding, Chengchao, et al.
Publicado: (2021)

Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies
por: Kaewchim, Kanasap, et al.
Publicado: (2023)

A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern In Vitro and In Vivo
por: Chiem, Kevin, et al.
Publicado: (2021)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
por: Liu, Zheng, et al.
Publicado: (2022)

A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern
por: Ahmed, Shahbaz, et al.
Publicado: (2021)

α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants
por: Zou, Jintao, et al.
Publicado: (2021)

Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen
por: Jiang, Min, et al.
Publicado: (2021)

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
por: Vanhove, Bernard, et al.
Publicado: (2021)

Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein
por: Castro, Julia T., et al.
Publicado: (2022)

Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response
por: Su, Qiu-Dong, et al.
Publicado: (2021)

Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants
por: Vanhove, Bernard, et al.
Publicado: (2023)

Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike
por: Changrob, Siriruk, et al.
Publicado: (2021)

Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike
por: Wilson, Patrick, et al.
Publicado: (2021)

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
por: Yuan, Mengqi, et al.
Publicado: (2023)

Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters
por: Piepenbrink, Michael S., et al.
Publicado: (2021)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
por: Ghaemi, Amir, et al.
Publicado: (2022)

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
por: VanBlargan, Laura A., et al.
Publicado: (2021)

RBD(206)-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern
por: Zhou, Chuge, et al.
Publicado: (2021)

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
por: Zhou, Yunjiao, et al.
Publicado: (2021)

Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants
por: Yi, Chunyan, et al.
Publicado: (2021)

High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells
por: Phetsouphanh, Chansavath, et al.
Publicado: (2022)

Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2
por: Park, Jun-Gyu, et al.
Publicado: (2021)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Yang, Lin, et al.
Publicado: (2021)

Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants
por: Rodriguez-Aponte, Sergio A., et al.
Publicado: (2023)

SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD
por: Septisetyani, Endah Puji, et al.
Publicado: (2021)

A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD
por: Liu, Shuo, et al.
Publicado: (2022)

Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2
por: Fragoso-Saavedra, Mario, et al.
Publicado: (2022)

Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern
por: Martín-Galiano, Antonio J., et al.
Publicado: (2021)

Neutralizing epitopes on Clostridioides difficile toxin A revealed by the structures of two camelid VHH antibodies
por: Chen, Baohua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_59896lv8j8bhau7ck81jkcehe6